Dossier assessment
Brigatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Brigatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Brigatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with ALK-positive advanced NSCLC who have not been previously treated with an ALK inhibitor
Patients with brain metastases at the start of treatment: indication of minor added benefit; patients without brain metastases at the start of treatment: hint of minor added benefit
Project details
- Project no.
- A20-42
- Commission
- Commission awarded on 29.04.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Brigatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42
Status: Commission completed
-
Addendum
Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42
Status: Commission completed